Molecular basis of ligand binding and receptor activation at the human A3 adenosine receptor

Abstract

Abstract Adenosine receptors (ARs: A 1 AR, A 2A AR, A 2B AR, and A 3 AR) are crucial therapeutic targets; however, developing selective, efficacious drugs for them remains a significant challenge. Here, we present high-resolution cryo-electron microscopy (cryo-EM) structures of the human A 3 AR in three distinct functional states: bound to the endogenous agonist adenosine, the clinically relevant agonist Piclidenoson, and the covalent antagonist LUF7602. These structures, complemented by mutagenesis and pharmacological studies, reveal an A 3 AR activation mechanism that involves an extensive hydrogen bond network from the extracellular surface down to the orthosteric binding site. In addition, we identify a cryptic pocket that accommodates the N 6 -iodobenzyl group of Piclidenoson through a ligand-dependent conformational change of M174 5.35 . Our comprehensive structural and functional characterisation of A 3 AR advances our understanding of adenosine receptor pharmacology and establishes a foundation for developing more selective therapeutics for various disorders, including inflammatory diseases, cancer, and glaucoma.